Company / Capital Expenditures
Matinas BioPharma Holdings, Inc. Capital Expenditures History
FY2015-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$892.0K
FY2023
5-year range
$5.7K / $892.0K
FY2019-FY2023
Trend
+243.1%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures changed +243% YoY in FY2023, a notable deviation from the 7-year average annual change of +794%.
Based on SEC 10-K filings.
$892,000 in FY2023 with a 5-year CAGR of -1.1%.
Improved from $260,000 to $892,000 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +437.4%
- 5-Year CAGR
- -1.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -1.1%, indicating a declining trend.
- In FY2023, capital expenditures increased 243.1% year-over-year.
- Peak capital expenditures was recorded in FY2018.
- Lowest capital expenditures in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -18.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | $892.0K | +243.1% |
| FY2022 | $260.0K | +0.0% |
| FY2021 | $260.0K | +4422.5% |
| FY2020 | $5.7K | -98.9% |
| FY2019 | $535.9K | -43.1% |
| FY2018 | $942.2K | +1136.8% |
| FY2017 | $76.2K | - |
| FY2016 | $0 | -100.0% |
| FY2015 | $76.2K | - |
As of FY2023 · SEC 10-K · Updated Jun 24, 2026